AcquisitionsMay 7, 2026, 04:20 PM
Artivion to Acquire Endospan for $135M Upfront; Q1 Revenue $116.3M
AI Summary
Artivion, Inc. announced it has exercised its option to acquire Endospan Ltd. for an upfront purchase price of approximately $135.0 million, net of previously extended loans, following U.S. FDA PMA approval for Endospan's Nexus™ Aortic Arch System. The acquisition is expected to close in Q2 2026 and will expand Artivion's aortic arch portfolio. Concurrently, Artivion reported Q1 2026 financial results, with revenue increasing 18% to $116.3 million and adjusted EBITDA growing 26% to $22.1 million. However, the company lowered its full-year 2026 revenue and adjusted EBITDA guidance.
Key Highlights
- Artivion exercised option to acquire Endospan for an upfront purchase price of $135.0 million, net of loans.
- Potential contingent consideration of up to $200.0 million based on future performance of Nexus™ product.
- Endospan received U.S. FDA PMA approval for its Nexus™ Aortic Arch System on April 2, 2026.
- Q1 2026 revenue was $116.3 million, an 18% increase (12% constant currency) from Q1 2025.
- Q1 2026 net income was $1.4 million, or $0.03 per fully diluted share.
- Q1 2026 adjusted EBITDA increased 26% to $22.1 million.
- Full-year 2026 revenue guidance lowered to $480-$496 million (7%-11% constant currency growth).
- Full-year 2026 adjusted EBITDA guidance lowered to $100-$107 million (12%-20% growth).